Too Crowded? ImmuneOncia Looks To Niches To Challenge PD-L1 Space
Pursues Two-Track Strategy
Executive Summary
ImmuneOncia CEO talks to Scrip about the development strategy for its anti-PD-L1 and anti-CD47 pipeline assets as well as the advantages of having Yuhan and Sorrento as its largest shareholders.